标题
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
作者
关键词
-
出版物
NATURE MEDICINE
Volume 25, Issue 7, Pages 1073-1081
出版商
Springer Science and Business Media LLC
发表日期
2019-07-04
DOI
10.1038/s41591-019-0499-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis
- (2018) William R. Coward et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma
- (2018) Marina Bárcena-Varela et al. HEPATOLOGY
- Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells
- (2018) Adam Cribbs et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
- (2018) Deng Pan et al. SCIENCE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Demethylase Kdm6a epigenetically promotes IL-6 and IFN-β production in macrophages
- (2017) Xia Li et al. JOURNAL OF AUTOIMMUNITY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
- (2017) Meredith L. Stone et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies
- (2017) Edurne San José-Enériz et al. Nature Communications
- Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer
- (2017) Cristina Segovia et al. Oncotarget
- Bladder cancer
- (2017) Oner Sanli et al. Nature Reviews Disease Primers
- Systemic therapy for bladder cancer finally comes into a new age
- (2016) Matthew Zibelman et al. Future Oncology
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies
- (2015) Julie Earl et al. BMC GENOMICS
- Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
- (2015) Katherine B. Chiappinelli et al. CELL
- G9a Inhibition Induces Autophagic Cell Death via AMPK/mTOR Pathway in Bladder Transitional Cell Carcinoma
- (2015) Feng Li et al. PLoS One
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- A Polycomb-mir200 loop regulates clinical outcome in bladder cancer
- (2015) Mónica Martínez-Fernández et al. Oncotarget
- Functional Role of G9a Histone Methyltransferase in Cancer
- (2015) Francesco Casciello et al. Frontiers in Immunology
- In Vivo Disruption of an Rb-E2F-Ezh2 Signaling Loop Causes Bladder Cancer
- (2014) M. Santos et al. CANCER RESEARCH
- The Histone H3 Lysine 9 Methyltransferases G9a and GLP Regulate Polycomb Repressive Complex 2-Mediated Gene Silencing
- (2014) Chiara Mozzetta et al. MOLECULAR CELL
- Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a
- (2014) Ramzi F. Sweis et al. ACS Medicinal Chemistry Letters
- Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
- (2013) Edward Y Chen et al. BMC BIOINFORMATICS
- EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
- (2013) J. Alfred Witjes et al. EUROPEAN UROLOGY
- PIK3CAgene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors
- (2013) Marta Dueñas et al. MOLECULAR CARCINOGENESIS
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- A Novel Tumor suppressor network in squamous malignancies
- (2012) Clotilde Costa et al. Scientific Reports
- Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines
- (2011) Arnulf Stenzl et al. EUROPEAN UROLOGY
- Akt Activation Synergizes with Trp53 Loss in Oral Epithelium to Produce a Novel Mouse Model for Head and Neck Squamous Cell Carcinoma
- (2009) M. Moral et al. CANCER RESEARCH
- Inactivation of p53 and Pten promotes invasive bladder cancer
- (2009) A. M. Puzio-Kuter et al. GENES & DEVELOPMENT
- Epigenetic Regulation of MicroRNAs in Acute Lymphoblastic Leukemia
- (2009) Jose Roman-Gomez et al. JOURNAL OF CLINICAL ONCOLOGY
- Negative Feedback Regulation of IFN- Pathway by IFN Regulatory Factor 2 in Esophageal Cancers
- (2008) Y. Wang et al. CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started